The PopVax Chronicles

Launching the RNA Foundry to design & manufacture personalized cancer vaccines

Starting with an open source cancer vaccine for Yash Bindal

Nov 13 • Soham Sankaran, Dhruv Arora, and PopVax

7

2

1:00

October 2026

PopVax Goes Clinical

First participants safely dosed in Melbourne, Australia, on August 31, 2026, in the first-in-human trial of our broadly-protective COVID-19 vaccine…

Oct 10 • Soham Sankaran

40

5

8

June 2026

Apocalypse Later: Announcing PopVax Biosecurity

Why PopVax is building the Immune Engine to develop and deploy new medicines against AI-designed viruses in weeks, not years

Jun 8 • Hannah Herzig and Soham Sankaran

26

2

3

April 2026

One hundred million silver bullets: Generative medicine vs. cancer

Two tumours

Apr 15 • Soham Sankaran

43

11

March 2026

v/acc: PopVax’s plan to save 1 million lives each year by massively accelerating vaccine development

The million lives mission

Mar 17 • Soham Sankaran

25

2

8

January 2025

Potent, broadly-protective flu vaccines to protect against potential pandemic influenza viruses such as H5N1

PopVax’s influenza vaccine designs elicit as much as 250x greater antibody titer against seasonal strains than existing approved flu vaccines, as well…

Jan 3, 2025 • Soham Sankaran

7

1

December 2024

August 2023

The unlikely, inevitable founding of PopVax, Part I: Three meetings and six million funerals

Broadly-protective mRNA vaccines to save millions of lives

Aug 20, 2023 • Soham Sankaran

28